2,066 reports of this reaction
4.1% of all GUSELKUMAB reports
#4 most reported adverse reaction
PSORIASIS is the #4 most commonly reported adverse reaction for GUSELKUMAB, manufactured by Janssen Biotech, Inc.. There are 2,066 FDA adverse event reports linking GUSELKUMAB to PSORIASIS. This represents approximately 4.1% of all 50,420 adverse event reports for this drug.
Patients taking GUSELKUMAB who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is moderately reported among GUSELKUMAB users, representing a notable but not dominant share of adverse events.
In addition to psoriasis, the following adverse reactions have been reported for GUSELKUMAB:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 2,066 FDA reports for GUSELKUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 4.1% of all adverse event reports for GUSELKUMAB, making it a notable side effect.
If you experience psoriasis while taking GUSELKUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.